Alvotech develops and manufactures biosimilar medicines—lower-cost versions of complex biologic drugs—for global markets. Headquartered in Iceland, it pursues a vertically integrated model spanning cell-line development through fill-finish manufacturing, while partnering with commercial distributors for sales. Its pipeline targets areas such as autoimmune disease, ophthalmology, osteoporosis, and oncology, aiming to broaden access to affordable biologics.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 132.8 | — | 109.7 | — |
| Q2 2025 | 173.2 | — | 32 | — |
| Q3 2025 | 113.7 | — | -5.3 | — |
| Q4 2025 | 166.6 | — | -108.5 | — |
| Q1 2026 | 105.9 | -20.3% | 1 | -99.1% |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Vir Biotechnology, Inc. (VIR), Sonos, Inc. (SONO), Target Hospitality Corp. (TH), Blue Bird Corporation (BLBD), Strategic Education, Inc. (STRA), Concentrix Corporation (CNXC)